SION-719

SION-719 is a novel small molecule drug developed by Sionna Therapeutics for the treatment of cystic fibrosis. It acts as a stabilizer of the first nucleotide-binding domain (NBD1) of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, targeting a mechanistically unique site compared to existing CFTR modulators. By stabilizing NBD1, SION-719 aims to restore wild-type CFTR function and improve chloride transport in patients with cystic fibrosis. The drug is being evaluated as an add-on therapy to standard-of-care (SOC) CFTR modulators, with preclinical and early clinical data suggesting potential synergistic effects and clinically meaningful benefits for patients who remain underserved by current treatments[2][4][5][7].